Multidisciplinary treatment approach of Morquio syndrome (mucopolysaccharidosis type IVA)

被引:1
|
作者
Önçag, G
Erdinç, AME
Cal, E
机构
[1] Univ Ege, Dept Orthodont, Fac Dent, TR-35100 Izmir, Turkey
[2] Univ Ege, Dept Prosthodont, Fac Dent, TR-35100 Izmir, Turkey
关键词
multidisciplinary treatment; Morquio syndrome;
D O I
暂无
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Morquio syndrome (mucopolysaccharidosis type IVA) is an autosomal recessive disorder caused by the accumulation of mucopolysaccharides in lysosomes because of the deficiency of N-acetylgalactosamine-6-sulphate sulphatase. Patients with Morquio syndrome often need orthodontic treatment. This study demonstrates the correction of malocclusion by orthodontic treatment and the improvement of the masticatory function by prosthodontic treatment in a male patient affected by Morquio syndrome. Labial inclinations of mandibular and maxillary anterior teeth were corrected, and spaces necessary for prosthodontic restorations were preserved. After this procedure, the restorations were made, and Hawley appliances were used in both jaws for retention. Patient satisfaction and an acceptable occlusal relationship were achieved by following an optimal treatment plan when considering the general status of the patient with Morquio syndrome.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 50 条
  • [1] Bone health in mucopolysaccharidosis type IVA (Morquio syndrome)
    Mitchell, John
    Ben Amor, Mouna
    Veilleux, Louis-Nicholas
    Steinmetz, Jason
    Rauch, Frank
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S78 - S78
  • [2] Mucopolysaccharidosis type IVA (Morquio syndrome): A clinical review
    Northover, H
    Cowie, RA
    Wraith, JE
    JOURNAL OF INHERITED METABOLIC DISEASE, 1996, 19 (03) : 357 - 365
  • [3] Therapies of mucopolysaccharidosis IVA (Morquio A syndrome)
    Tomatsu, Shunji
    Almeciga-Diaz, Carlos J.
    Barbosa, Hector
    Montano, Adriana M.
    Barrera, Luis A.
    Shimada, Tsutomu
    Yasuda, Eriko
    Mackenzie, William G.
    Mason, Robert W.
    Suzuki, Yasuyuki
    Orii, Kenji E.
    Orii, Tadao
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (10): : 805 - 818
  • [4] Mucopolysaccharidosis type IVA (Morquio syndrome) A rare case report
    Amiri, M. Mahdavi
    Khoshaeen, A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1789 - 1790
  • [5] Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome)
    Hendriksz, Christian J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (12) : 1521 - 1532
  • [6] Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome)
    Kampmann, Christoph
    Abu-Tair, Tariq
    Goekce, Seyfullah
    Lampe, Christina
    Reinke, Joerg
    Mengel, Eugen
    Hennermann, Julia B.
    Wiethoff, Christiane M.
    PLOS ONE, 2016, 11 (09):
  • [7] Mucopolysaccharidosis type IVA (Morquio syndrome) in Thai children: Report of 3 cases
    Wasant, P.
    Liammongkolkul, S.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 155 - 155
  • [8] Natural history of the oldest known females with mucopolysaccharidosis type IVA (Morquio A syndrome)
    Peretz, Ryan H.
    Flora, Christina H.
    Adams, Darius J.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2020, 182 (06) : 1491 - 1495
  • [9] Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A Syndrome)
    Lyseng-Williamson, Katherine A.
    BIODRUGS, 2014, 28 (05) : 465 - 475
  • [10] Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A Syndrome)
    Katherine A. Lyseng-Williamson
    BioDrugs, 2014, 28 : 465 - 475